CD274 and neoplasm: At the same time, the Atezolizumab (anti‐PD‐L1) + Bevacizumab (anti‐VEGF) combination has become the first‐line regimen for advanced HCC, enhancing tumor immunogenicity by suppressing Treg cells and normalizing tumor vasculature [8].